Page 70 - Read Online

Torres et al. J Cancer Metastasis Treat 2018;4:4 I http://dx.doi.org/10.20517/2394-4722.2017.49 Page 17 of 25

2013;8:101.
8. Khawar I, Kim J, Kuh H. Improving drug delivery to solid tumors: Priming the tumor microenvironment. J Control Release
2015;201:78-89.
9. Nagarsheth N, Wicha M, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev
Immunol 2017;17:559-72.
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF,
Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow
MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and
ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
11. Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey C, Lao C, Wagstaff J, Schadendorf D, Ferrucci P, Smylie
M, Dummer R, Hill A, Hogg D, Haanen J, Carlino M, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C,
Ascierto P, Long G, Cebon J, Sosman J, Postow M, Callahan M, Walker D, Rollin L, Bhore R, Hodi F, Larkin J. Overall survival with
combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 2017;377:345-56.
12. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat E, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG,
Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update
2016. Eur Urol 2017;71:447-61.
13. Roberts N, Zhang L, Janku F, Collins A, Bai R, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin
RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J,
Phillips B, Turner A, Klein MK, Post G, Diaz LA Jr, Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C, Huso DL,
Varterasian M, Saha S, Zhou S. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med
2014;6:249ra111.
14. Toneri M, Miwa S, Zhang Y, Hu C, Yano S, Matsumoto Y, Bouvet M, Nakanishi H, Hoffman RM, Zhao M. Tumor-targeting Salmonella
typhimurium A1-R inhibits human prostate cáncer experimental bone metástasis in mouse models. Oncotarget 2015;6:31335-43.
15. Laurence M, Yvonne P. Attenuated listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.
Front Cell Infect Microbiol 2014;4:51.
16. Gatenby R, Brown J. Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of
cancer. Biochim Biophys Acta 2017;1867:162-6.
17. Zheng S, Widschwendter M, Teschendorff A. Epigenetic drift, epigenetic clocks and cancer risk. Epigenomics 2016;8:705-19.
18. Grasso Frisan T. Bacterial genotoxins: merging the DNA damage response into infection biology. Biomolecules 2015;5:1762-82.
19. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000;100:57-70.
20. Behrens A, van Deursen J, Rudolph K, Schumacher B. Impact of genomic damage and ageing on stem cell function. Nat Cell Biol
2014;16:201-7.
21. Charni M, Aloni-Grinstein R, Molchadsky A, Rotter V. p53 on the crossroad between regeneration and cancer. Cell Death Differ
2016;24:8-14.
22. Xu JH, Hu SL, Shen GD, Shen G. Tumor suppressor genesand their underlying interactions in paclitaxel resistance in cancer therapy.
Cancer Cell Int 2016;16:13.
23. Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015;125:3347-55.
24. Garg A, Dudek A, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 2013;39:355-67.
25. Pritchard A, Hastie M, Neller M, Gorman J, Schmidt C, Hayward N. Exploration of peptides bound to MHC class I molecules in
melanoma. Pigment Cell Melanoma Res 2015;28:281-94.
26. Galon J, Angell H, Bedognetti D, Marincola F. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic
signatures. Immunity 2013;39:11-26.
27. Romee R, Leong J, Fehniger T. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica
(Cairo) 2014;2014:205796.
28. Gajewski T, Schreiber H, Fu Y. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
29. Payne K, Bear H, Manjili M. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-1779-
1794.tumor efficacy. Future Oncol 2014;10:1779-94.
30. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
31. Jandus C, Boligan K, Chijioke O, Liu H, Dahlhaus M, Démoulins T, Schneider C, Wehrli M, Hunger RE, Baerlocher GM, Simon
HU, Romero P, Münz C, von Gunten S. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor
immunosurveillance. J Clin Invest 2014;124:1810-20.
32. Morvan M, Lanier L. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 2015;16:7-19.
33. Crouse J, Xu H, Lang P, Oxenius A. NK cells regulating T cell responses: mechanisms and outcome. Trends Immunol 2015;36:49-58.
34. D’Eliseo D, Manzi L, Velotti F. Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death
(ICD) in human bladder cancer cells. Cell Stress Chaperones 2013;18:801-8.
35. Deauvieau F, Ollion V, Doffin A, Achard C, Fonteneau J, Verronese E, Durand I, Ghittoni R, Marvel J, Dezutter-Dambuyant C, Walzer
T, Vie H, Perrot I, Goutagny N, Caux C, Valladeau-Guilemond J. Human natural killer cells promote cross-presentation of tumor cell-
derived antigens by dendritic cells. Int J Cancer 2014;136:1085-94.
36. Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Crit Rev Oncog 2014;19:67-75.